Sun Pharma Advanced Research Company Limited (NSE:SPARC)
India · Delayed Price · Currency is INR 206.50
-1.93 (-0.93%)
Jul 31, 2026, 3:30 PM IST
NSE:SPARC Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 391.48 | 717.66 | 755.45 | 2,388 | 1,372 |
Other Revenue | 18,400 | - | - | - | - |
| 18,792 | 717.66 | 755.45 | 2,388 | 1,372 | |
Revenue Growth | 2518.47% | -5.00% | -68.36% | 73.98% | -45.74% |
Cost of Revenue | 299.46 | 302 | 364.39 | 283.24 | 235.6 |
Gross Profit | 18,492 | 415.66 | 391.07 | 2,105 | 1,137 |
Selling, General & Admin | 1,879 | 2,454 | 2,944 | 2,390 | 1,658 |
Research & Development | 226.64 | 813.34 | 1,014 | 1,495 | 1,084 |
Other Operating Expenses | 295.96 | 366.04 | 424.55 | 339.19 | 254.38 |
Operating Expenses | 2,503 | 3,756 | 4,506 | 4,341 | 3,098 |
Operating Income | 15,989 | -3,341 | -4,115 | -2,236 | -1,961 |
Interest Expense | -314.97 | -84.57 | -11.75 | -76.35 | -133.29 |
Interest & Investment Income | 102.87 | 6.82 | 254.76 | 75.95 | 14.1 |
Currency Exchange Gain (Loss) | -101.31 | -14.69 | -31.03 | -20.69 | -8.39 |
Other Non Operating Income (Expenses) | -24.53 | -5.6 | -2.82 | 0.17 | 0.77 |
EBT Excluding Unusual Items | 15,651 | -3,439 | -3,906 | -2,257 | -2,088 |
Gain (Loss) on Sale of Investments | - | 10.55 | 31.73 | 32.65 | 4.64 |
Gain (Loss) on Sale of Assets | 2.39 | 0.33 | 5.82 | -1.13 | 48.93 |
Other Unusual Items | -123.65 | - | - | - | - |
Pretax Income | 15,530 | -3,428 | -3,868 | -2,226 | -2,034 |
Income Tax Expense | -1.94 | -2.72 | 3.82 | - | - |
Net Income | 15,532 | -3,425 | -3,872 | -2,226 | -2,034 |
Net Income to Common | 15,532 | -3,425 | -3,872 | -2,226 | -2,034 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 325 | 325 | 325 | 285 | 263 |
Shares Outstanding (Diluted) | 325 | 325 | 325 | 285 | 263 |
Shares Change | - | - | 13.99% | 8.19% | 0.42% |
EPS (Basic) | 47.86 | -10.55 | -11.93 | -7.82 | -7.73 |
EPS (Diluted) | 47.86 | -10.55 | -11.93 | -7.82 | -7.73 |
EPS Growth | - | - | - | - | - |
Free Cash Flow | -2,626 | -3,706 | -4,557 | -845.05 | -2,409 |
Free Cash Flow Per Share | -8.09 | -11.42 | -14.04 | -2.97 | -9.15 |
Gross Margin | 98.41% | 57.92% | 51.77% | 88.14% | 82.83% |
Operating Margin | 85.09% | -465.49% | -544.71% | -93.66% | -142.86% |
Profit Margin | 82.65% | -477.26% | -512.56% | -93.22% | -148.20% |
Free Cash Flow Margin | -13.98% | -516.45% | -603.21% | -35.39% | -175.53% |
EBITDA | 16,068 | -3,255 | -4,025 | -2,149 | -1,877 |
EBITDA Margin | 85.51% | - | - | -89.99% | -136.79% |
D&A For EBITDA | 78.65 | 85.4 | 89.86 | 87.74 | 83.25 |
EBIT | 15,989 | -3,341 | -4,115 | -2,236 | -1,961 |
EBIT Margin | 85.09% | - | - | -93.66% | -142.86% |
Revenue as Reported | 18,901 | 735.57 | 1,050 | 2,497 | 1,441 |